10-16933122-C-T
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_001081.4(CUBN):c.6089G>A(p.Arg2030Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00026 in 1,613,976 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001081.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CUBN | NM_001081.4 | c.6089G>A | p.Arg2030Gln | missense_variant | 40/67 | ENST00000377833.10 | NP_001072.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CUBN | ENST00000377833.10 | c.6089G>A | p.Arg2030Gln | missense_variant | 40/67 | 1 | NM_001081.4 | ENSP00000367064.4 |
Frequencies
GnomAD3 genomes AF: 0.000460 AC: 70AN: 152020Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000760 AC: 191AN: 251264Hom.: 0 AF XY: 0.000648 AC XY: 88AN XY: 135778
GnomAD4 exome AF: 0.000240 AC: 351AN: 1461838Hom.: 3 Cov.: 32 AF XY: 0.000217 AC XY: 158AN XY: 727218
GnomAD4 genome AF: 0.000454 AC: 69AN: 152138Hom.: 0 Cov.: 32 AF XY: 0.000578 AC XY: 43AN XY: 74372
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 12, 2021 | The c.6089G>A (p.R2030Q) alteration is located in exon 40 (coding exon 40) of the CUBN gene. This alteration results from a G to A substitution at nucleotide position 6089, causing the arginine (R) at amino acid position 2030 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Imerslund-Grasbeck syndrome type 1 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. - |
Imerslund-Grasbeck syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at